Directorate Change

BTG plc: Garry Watts to succeed Dr John Brown as non-executive Chairman

London, UK, 11 November 2011: BTG plc (LSE: BGC), the specialist healthcare company, today announces that Garry Watts, FCA, MBE, is to succeed Dr John Brown, CBE, FRSE, as non-executive Chairman, effective from 1 January 2012.

Garry Watts is Chairman of the Spire Healthcare group of private hospitals. He is the Senior Independent Director at Stagecoach Group plc and a non-executive Director of Coca-Cola Enterprises, Inc.

Garry was Chief Executive Officer of SSL International plc for seven years until its sale in November 2010 to Reckitt Benckiser. He was a member of the supervisory board of the UK's Medicines Healthcare Research Agency for 17 years until 2008 and is a former executive director of Medeva plc and Celltech plc. He was also a non-executive Director of Protherics plc until its acquisition by BTG in December 2008.

Mr Watts commented: "I am delighted to be joining BTG at such an exciting time for the company. Under John's chairmanship BTG has significantly grown in value as it has transformed into a specialist healthcare company marketing its own products. I now look forward to working with the Board and the wider BTG team on the next stage of the company's evolution."

Dr John Brown added: "I am very pleased to welcome Garry to BTG. He has the commercial and sector experience to guide the company through its next phase of growth. I have very much enjoyed my role as Chairman of BTG over the past several years. I leave the business in excellent shape and I wish Garry, Louise and the team every success."

Louise Makin, CEO, said: "On behalf of the Board, I'd like to thank John for his enormous contribution to BTG's development, including his overall stewardship of the business and the support he has given to us all throughout his tenure as Chairman. Garry brings a wealth of experience from the healthcare and other sectors that will be of great benefit to BTG and we all look forward to working with him."

There are no further details to be disclosed on the appointment of Garry Watts in relation to paragraph 9.6.13R of the Financial Services Authority Listing Rules.

For further information please contact:

About BTG

BTG is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company is seeking to acquire new products to develop and market to specialist physicians, and is building a sustainable business financed by revenues from sales of its own marketed products and from royalties and milestone payments on partnered products. For further information about BTG please visit our website at www.btgplc.com.